Loading...
Pfizer Inc. Delivers Resilient Q3 and 9M 2025 Performance with Strong EPS Outperformance, Cost Discipline and Strategic Repositioning
n/a
n/a
Wane_Investment_House's Fair Value
n/a
1Y
10.2%7D
0.6%1Y
10.2%7D
0.6%You can edit this narrative until Jan 5 1:00 PM. Then, changes will post as Updates.
Author's Valuation
US$25.58.1% overvalued intrinsic discount
Wane_Investment_House's Fair Value